wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33561602-FBC16C23-5091-49DA-A3E8-7CB026D6CD13
Q33561602-FBC16C23-5091-49DA-A3E8-7CB026D6CD13
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33561602-FBC16C23-5091-49DA-A3E8-7CB026D6CD13
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
P2860
Q33561602-FBC16C23-5091-49DA-A3E8-7CB026D6CD13
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33561602-FBC16C23-5091-49DA-A3E8-7CB026D6CD13
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3b88c953145e4044ad7ba917b8047766693b9039
P2860
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).